Genomma Lab Internacional Stock Performance
| GNMLF Stock | USD 1.27 0.00 0.00% |
On a scale of 0 to 100, Genomma Lab holds a performance score of 7. The company retains a Market Volatility (i.e., Beta) of 1.57, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Genomma Lab will likely underperform. Please check Genomma Lab's variance, potential upside, as well as the relationship between the Potential Upside and day median price , to make a quick decision on whether Genomma Lab's current trending patterns will revert.
Risk-Adjusted Performance
7 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Genomma Lab Internacional are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. Despite nearly uncertain essential indicators, Genomma Lab reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 2.1 B | |
| Total Cashflows From Investing Activities | -765.6 M |
Genomma |
Genomma Lab Relative Risk vs. Return Landscape
If you would invest 99.00 in Genomma Lab Internacional on August 24, 2024 and sell it today you would earn a total of 28.00 from holding Genomma Lab Internacional or generate 28.28% return on investment over 90 days. Genomma Lab Internacional is currently producing 0.5551% returns and takes up 5.7257% volatility of returns over 90 trading days. Put another way, 50% of traded pink sheets are less volatile than Genomma, and 89% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Genomma Lab Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Genomma Lab's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Genomma Lab Internacional, and traders can use it to determine the average amount a Genomma Lab's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0969
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | GNMLF | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.73 actual daily | 51 51% of assets are less volatile |
Expected Return
| 0.56 actual daily | 11 89% of assets have higher returns |
Risk-Adjusted Return
| 0.1 actual daily | 7 93% of assets perform better |
Based on monthly moving average Genomma Lab is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Genomma Lab by adding it to a well-diversified portfolio.
Genomma Lab Fundamentals Growth
Genomma Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Genomma Lab, and Genomma Lab fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Genomma Pink Sheet performance.
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0921 | |||
| Profit Margin | 0.08 % | |||
| Operating Margin | 0.20 % | |||
| Current Valuation | 1.09 B | |||
| Shares Outstanding | 1 B | |||
| Price To Earning | 11.09 X | |||
| Price To Book | 1.38 X | |||
| Price To Sales | 0.05 X | |||
| Revenue | 15.49 B | |||
| EBITDA | 2.84 B | |||
| Cash And Equivalents | 1.3 B | |||
| Cash Per Share | 1.30 X | |||
| Total Debt | 3.83 B | |||
| Debt To Equity | 0.51 % | |||
| Book Value Per Share | 10.98 X | |||
| Cash Flow From Operations | 1.47 B | |||
| Earnings Per Share | 0.07 X | |||
| Total Asset | 21.54 B | |||
About Genomma Lab Performance
By analyzing Genomma Lab's fundamental ratios, stakeholders can gain valuable insights into Genomma Lab's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Genomma Lab has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Genomma Lab has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, engages in the development, marketing, and sale of over-the-counter pharmaceutical and personal care products in Mexico and internationally. Genomma Lab Internacional, S.A.B. de C.V. was incorporated in 1996 and is based in Mexico City, Mexico. Genomma Lab operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 2327 people.Things to note about Genomma Lab Internacional performance evaluation
Checking the ongoing alerts about Genomma Lab for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Genomma Lab Internacional help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Genomma Lab is way too risky over 90 days horizon | |
| Genomma Lab may become a speculative penny stock | |
| Genomma Lab appears to be risky and price may revert if volatility continues | |
| About 29.0% of the company shares are held by company insiders |
- Analyzing Genomma Lab's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Genomma Lab's stock is overvalued or undervalued compared to its peers.
- Examining Genomma Lab's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Genomma Lab's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Genomma Lab's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Genomma Lab's pink sheet. These opinions can provide insight into Genomma Lab's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Genomma Pink Sheet analysis
When running Genomma Lab's price analysis, check to measure Genomma Lab's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genomma Lab is operating at the current time. Most of Genomma Lab's value examination focuses on studying past and present price action to predict the probability of Genomma Lab's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genomma Lab's price. Additionally, you may evaluate how the addition of Genomma Lab to your portfolios can decrease your overall portfolio volatility.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |